29. Kerkhofs TM, Derijks LJ, Ettaieb H, et al. Development of a Pharmacokinetic Model of Mitotane: Toward Personalized Dosing in Adrenocortical Carcinoma. Ther Drug Monit 2015; 37: 58–65. https://doi.org/10.1097/FTD.0000000000000102
30. Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma Concentrations of o′,p′DDD, o′,p′DDA, and o′,p′DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study. J Clin Endocrinol Metab 2011; 96: 1844–1851. https://doi.org/10.1210/jc.2010-2676
31. von Slooten H, van Seters AP, Smeenk D, et al. O,p′-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol 1982; 9: 85–88. https://doi.org/10.1007/bf00265384
32. De Francia S, Pirro E, Zappia F, et al. A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 837: 69–75. https://doi.org/10.1016/j.jchromb.2006.04.005
33. Lindhe Ö, Lund BO, Bergman Å, et al. Irreversible Binding and Adrenocorticolytic Activity of the DDT Metabolite 3-Methylsulfonyl-DDE Examined in Tissue-Slice Culture. Environ Health Perspect 2001; 109: 105–110. https://doi.org/10.1289/ehp.109-1240628
34. Lindhe Ö, Skogseid B, Brandt I. Cytochrome P450-Catalyzed Binding of 3-Methylsulfonyl-DDE and o,p′-DDD in Human Adrenal Zona fasciculata/Reticularis . J Clin Endocrinol Metab 2002; 87: 1319–1326. https://doi.org/10.1210/jcem.87.3.8281
35. Kroiss M, Plonné D, Kendl S, et al. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol 2016; 174: 343–353. https://doi.org/10.1530/EJE-15-0946